Imago Biosciences Inc Quick Ratio (IMGO) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Imago Biosciences Inc   (NASDAQ: IMGO)

Imago Biosciences Inc 's Quick Ratio

IMGO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Imago Biosciences Inc 's Cash & cash equivalent, this led to improvement in Imago Biosciences Inc 's Quick Ratio to 25.43, above Imago Biosciences Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 37 other companies have achieved higher Quick Ratio than Imago Biosciences Inc in third quarter 2022. While Quick Ratio total ranking has improved so far during the Q3 2022 to 160, from total ranking in the second quarter 2022 at 186.

Explain Quick Ratio?
How much Cash & cash equivalents IMGO´s has?
What are IMGO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMGO Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change -21.28 % 37.19 % 79.41 % - -
Y / Y Cash & cash equivalent Change -22.55 % 134.27 % -22.81 % - -
Quick Ratio MRQ 25.43 21.66 15.91 36.98 25.85
IMGO's Total Ranking # 160 # 186 # 281 # 200 # 158
Seq. Current Liabilities Change -20.04 % -32.17 % 120 % -34.03 % 39.34 %
Seq. Cash & cash equivalent Change -6.1 % -7.68 % -5.33 % -5.62 % 184 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 38
Healthcare Sector # 54
Overall Market # 160


Quick Ratio Statistics
High Average Low
25.85 20.51 12.68
(Sep 30 2021)   (Jun 30 2021)




Financial Statements
Imago Biosciences Inc 's Current Liabilities $ 7 Millions Visit IMGO's Balance sheet
Imago Biosciences Inc 's Cash & cash equivalent $ 178 Millions Visit IMGO's Balance sheet
Source of IMGO's Sales Visit IMGO's Sales by Geography


Cumulative Imago Biosciences Inc 's Quick Ratio

IMGO's Quick Ratio for the trailling 12 Months

IMGO Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 53.68 % 168.28 % 373.28 % - -
Y / Y Cash & cash equivalent TTM Growth 36.94 % 142.59 % 175.54 % - -
Quick Ratio TTM 22.88 23.11 21.53 28.02 25.68
Total Ranking TTM # 3556 # 156 # 3497 # 3702 # 178
Seq. Current Liabilities TTM Growth -5.19 % 6.97 % 20.16 % 26.11 % 65.5 %
Seq. Cash & cash equivalent TTM Growth -6.16 % 14.82 % -7.65 % 37.61 % 66.24 %

Quick ratio ranking by company, industry and sector >> Back to IMGO Financial Strength Comparisons >> Go to Compare IMGO Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in IMGO's Current Liabilities to $7.02 millions, cumulative Quick Ratio to 22.88 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 553 other companies have achieved higher Quick Ratio than Imago Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 156 to 3556.

Explain Quick Ratio?
How much Cash & cash equivalents IMGO´s has?
What are IMGO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 554
Healthcare Sector # 1083
Within the Market # 3556


trailing twelve months Quick Ratio Statistics
High Average Low
20.72 18.03 14.9
(Jun 30 2022)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Greenwich Lifesciences Inc   65.73 $ 15.638  Millions$ 0.238  Millions
Rezolute Inc   63.53 $ 154.322  Millions$ 2.429  Millions
Xbiotech Inc   61.51 $ 220.100  Millions$ 3.578  Millions
Gh Research Plc  56.52 $ 256.939  Millions$ 4.546  Millions
Cohbar Inc   52.43 $ 18.339  Millions$ 0.350  Millions
Nuvation Bio Inc   48.10 $ 673.945  Millions$ 14.011  Millions
Tyra Biosciences Inc   47.95 $ 263.211  Millions$ 5.489  Millions
Ionis Pharmaceuticals Inc   44.01 $ 6,537.909  Millions$ 148.563  Millions
Atea Pharmaceuticals Inc   42.53 $ 664.975  Millions$ 15.634  Millions
Xenon Pharmaceuticals Inc   41.08 $ 638.185  Millions$ 15.537  Millions
Atossa Therapeutics Inc   40.96 $ 117.477  Millions$ 2.868  Millions
Lexaria Bioscience Corp   40.68 $ 6.161  Millions$ 0.151  Millions
Silo Pharma Inc  39.25 $ 12.253  Millions$ 0.312  Millions
Tao Synergies Inc   38.52 $ 26.334  Millions$ 0.684  Millions
Briacell Therapeutics Corp   38.45 $ 37.452  Millions$ 0.974  Millions
Artelo Biosciences Inc   37.49 $ 17.995  Millions$ 0.480  Millions
Edgewise Therapeutics inc   35.11 $ 364.822  Millions$ 10.390  Millions
Design Therapeutics Inc   33.06 $ 344.233  Millions$ 10.412  Millions
Cocrystal Pharma Inc   30.52 $ 42.056  Millions$ 1.378  Millions
Kezar Life Sciences Inc   30.26 $ 290.383  Millions$ 9.595  Millions
Karuna Therapeutics Inc   29.26 $ 1,192.034  Millions$ 40.745  Millions
Merrimack Pharmaceuticals Inc  29.22 $ 13.091  Millions$ 0.448  Millions
Aprea Therapeutics Inc   29.15 $ 33.113  Millions$ 1.136  Millions
Rafael Holdings Inc  29.07 $ 93.187  Millions$ 3.206  Millions
Anebulo Pharmaceuticals Inc   27.52 $ 19.214  Millions$ 0.698  Millions
Theseus Pharmaceuticals Inc   27.21 $ 212.434  Millions$ 7.806  Millions
Spruce Biosciences Inc   26.61 $ 90.400  Millions$ 3.397  Millions
Cyteir Therapeutics Inc   26.46 $ 153.890  Millions$ 5.816  Millions
Immix Biopharma Inc   26.17 $ 16.917  Millions$ 0.647  Millions
Savara Inc   25.97 $ 134.077  Millions$ 5.163  Millions

Date modified: 2026-09-08T15:10:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.